Rockefeller Capital Management L.P. Denali Therapeutics Inc. Transaction History

Rockefeller Capital Management L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$23.37 - $32.96 $3,832 - $5,405	164 Added 1.88%	8,888 $262,000
Q1 2023 May 17, 2023	SELL	$21.91 - $32.67 $24,845 - $37,047	-1,134 Reduced 11.5%	8,724 $200,000
Q4 2022 Mar 06, 2023	SELL	$26.28 - $33.92 $51,929 - $67,025	-1,976 Reduced 16.7%	9,858 $273,000
Q3 2022 Nov 02, 2022	BUY	$25.97 - $38.53 $15,685 - $23,272	604 Added 5.38%	11,834 $362,000
Q2 2022 Aug 12, 2022	SELL	$20.88 - $35.19 $175,851 - $296,370	-8,422 Reduced 42.86%	11,230 $330,000
Q1 2022 May 13, 2022	BUY	$29.0 - $47.27 $92,626 - $150,980	3,194 Added 19.41%	19,652 $631,000
Q4 2021 Feb 14, 2022	BUY	$42.59 - $55.02 $70,656 - $91,278	1,659 Added 11.21%	16,458 $733,000
Q3 2021 Nov 12, 2021	BUY	$48.48 - $78.23 $368,060 - $593,922	7,592 Added 105.34%	14,799 $745,000
Q2 2021 Aug 10, 2021	BUY	$50.3 - $78.44 $141,695 - $220,965	2,817 Added 64.17%	7,207 $564,000
Q1 2021 May 11, 2021	BUY	$53.8 - $81.53 $101,682 - $154,091	1,890 Added 75.6%	4,390 $249,000
Q3 2020 Nov 13, 2020	BUY	$23.13 - $38.84 $57,825 - $97,100	2,500 New	2,500 $89,000

241

121M

80K

36.8K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.78B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.